Onc.AI

AI-powered technology bringing clarity to cancer treatment

health AIdigital healthmedtech

Visit website

StageSeries A

Raised$33.96M

Founded2020

Employees20

LocationSan Carlos, CA

Business modelB2B, SaaS

About

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.

Product

Value proposition: Leverages real-world oncology data and AI to assist pharma and clinicians in decision-making across oncology, including predictive/prognostic models and FDA-designated breakthroughs.
Target customers: pharma companies, clinical researchers, oncology care teams
Pricing: not publicly disclosed
Regulatory: FDA Breakthrough Device Designation (for Serial CT/Score model)

Founders

Akshay Nanduri — CEO and Co-Founder
Salmaan Ahmed — VP of Software and Co-Founder

Products

Onclara EvaluateOnclara IOOnclara platform

Key features

predictive and prognostic AI models for oncologyreal-world dataset trainingFDA Breakthrough Device-designated modelsclinical decision support for trial design and treatment decisionsimaging- and radiomics-informed analytics

Technologies

AI/MLradiomicsdeep learningreal-world data (RWD)clinical decision supportpredictive modeling

Integrations

electronic health records (EHR)clinical trial data systemspharma data platformspotential interoperability with hospital IT systems

Target conditions

cancermetastatic NSCLConcology indications

Care settings

pharma R&Dhospital/clinicclinical trialsvirtual/remote collaboration

Certifications

FDA Breakthrough Device Designation (for specific models)

Notable customers

pharma companies

Partnerships

BusinessWire press releases with technology milestones (unspecified partners)research/insights partnerships (Decibio interview)

Awards

FDA Breakthrough Device Designation (for Serial CT Score)NCI grant award (2M) for AI-based clinical decision support for metastatic NSCLC)

Traction metrics

Series A $25M financingFDA Breakthrough Device DesignationNCI grant for metastatic NSCLC

Investors

National Cancer InstituteAccompliceThe Blue Venture FundDigitalis VenturesKdT VenturesMassMutualAction Potential Venture CapitalDavid Diaz-CasariegoEmir SandhuLifeX VenturesJohn CapodilupoThomas HawesJonathan FlemingStanley MarksT. Chen Fong

News

Onc.AI Awarded FDA Breakthrough Device Designation for Serial CT Response Score Deep Learning Model · 2025-02-06T00:00:00.000Z
Onc.AI Lung Clinical Management validated in real-world dataset and Pfizer clinical trial - onc.ai · 2025-02-05T15:24:29.000Z
Onc.AI to Present Breakthrough Deep Learning Radiomic Biomarker Results at 2025 ASCO Annual Meeting · 2025-05-30T10:03:00.000Z
Onc.AI Awarded $2 Million National Cancer Institute Grant to Advance AI-based Clinical Decision Support for Metastatic NSCLC · 2024-10-24T00:00:00.000Z
Onc.AI Announces Positive External Validation of Onclara IO, a CT Imaging AI Biomarker for First-Line Immunotherapy in PD-L1-High Metastatic Non-Small Cell Lung Cancer | Morningstar · 2026-05-28T11:00:00.000Z
Onc.AI's lung cancer analysis tool gets FDA Breakthrough Device Designation - Mugglehead Investment Magazine · 2025-02-12T00:21:55.000Z

Browse similar startups

Related startups

OnPoint Vision, Inc. — Aliso Viejo, CA
Oral Genome — Carlsbad, CA
Orbits Oncology — San Francisco, CA
Pacific Pediatric Cardiology — Victorville, CA
Parakeet Health — San Francisco, CA
PathoGene, Inc. — Monrovia, CA
Plexis.ai (Techstars '25) — Delaware, DE
Rovi Health (YC F25) — Philadelphia, PA
Tally — Washington, DC
Unite Genomics — San Mateo, CA
Xeomics — Boston, MA
Althea Health — San Jose, CA

Profile updated Jul 29, 2026. Sources: onc.ai